Literature DB >> 32224832

Use of Coagulation Point-of-Care Tests in the Management of Anticoagulation and Bleeding in Pediatric Cardiac Surgery: A Systematic Review.

Paolo Bianchi1, Camilla Beccaris2, Martina Norbert3, Bradley Dunlop3, Marco Ranucci4.   

Abstract

Bleeding and coagulation management are essential aspects in the management of neonates and children undergoing cardiac surgery. The use of point-of-care tests (POCTs) in a pediatric setting is not as widely used as in the adult setting. This systematic review aims to summarize the evidence showed by the literature regarding the use of POCTs in children undergoing cardiac surgery. We included all studies examining the pediatric population (<18 years old) undergoing cardiac surgery in which the coagulation profile was assessed with POCTs. Three electronic databases (PubMed, Embase, and the Cochrane Controlled Clinical Trials register) were searched. Tests involved were heparin effect tests, viscoelastic tests, and platelet function tests. Due to the wide heterogeneity of the patients and tests studied, a formal meta-analysis was impossible, and the results are therefore presented through a systematic review. Eighty articles were found, of which 47 are presented in this review. At present, literature data are too weak to define POCTs as a "gold standard" for the treatment of perioperative bleeding in pediatric cardiac surgery. Nevertheless, introduction of POCTs into postoperative algorithms has shown to improve bleeding management, patient outcome, and cost efficiency.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32224832     DOI: 10.1213/ANE.0000000000004563

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  1 in total

1.  Monitoring of COVID-19-Associated Coagulopathy and Anticoagulation with Thromboelastometry.

Authors:  Daniel Katz; Patrick Maher; Chloe Getrajdman; Joshua Hamburger; Shan Zhao; Jonathan Madek; Himani Bhatt; Matthew Levin; Klaus Görlinger
Journal:  Transfus Med Hemother       Date:  2021-02-26       Impact factor: 3.747

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.